Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

[How to handle a non-resolving pneumonia?]

Lechartier B, Prella M, Manuel O, Nicod LP.

Rev Med Suisse. 2016 Nov 16;12(539):1942-1947. French.

PMID:
28696635
2.

Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.

Foo CS, Lechartier B, Kolly GS, Boy-Röttger S, Neres J, Rybniker J, Lupien A, Sala C, Piton J, Cole ST.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6451-6459. doi: 10.1128/AAC.01523-16. Print 2016 Nov.

3.

Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis.

Lechartier B, Cole ST.

Antimicrob Agents Chemother. 2015 Aug;59(8):4457-63. doi: 10.1128/AAC.00395-15. Epub 2015 May 18.

4.

Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis.

Vocat A, Hartkoorn RC, Lechartier B, Zhang M, Dhar N, Cole ST, Sala C.

Antimicrob Agents Chemother. 2015 Jul;59(7):4012-9. doi: 10.1128/AAC.00528-15. Epub 2015 Apr 20.

5.

Multitarget drug discovery for tuberculosis and other infectious diseases.

Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V, Lechartier B, Fontes FL, Yang H, Rao G, Zhu W, Gulati A, No JH, Cintra G, Bogue S, Liu YL, Molohon K, Orlean P, Mitchell DA, Freitas-Junior L, Ren F, Sun H, Jiang T, Li Y, Guo RT, Cole ST, Gennis RB, Crick DC, Oldfield E.

J Med Chem. 2014 Apr 10;57(7):3126-39. doi: 10.1021/jm500131s. Epub 2014 Apr 1.

6.

Towards a new combination therapy for tuberculosis with next generation benzothiazinones.

Makarov V, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA, Hartkoorn RC, Ryabova OB, Vocat A, Decosterd LA, Widmer N, Buclin T, Bitter W, Andries K, Pojer F, Dyson PJ, Cole ST.

EMBO Mol Med. 2014 Mar;6(3):372-83. doi: 10.1002/emmm.201303575. Epub 2014 Feb 5.

7.

Tuberculosis drug discovery in the post-post-genomic era.

Lechartier B, Rybniker J, Zumla A, Cole ST.

EMBO Mol Med. 2014 Feb;6(2):158-68. doi: 10.1002/emmm.201201772. Epub 2014 Jan 8. Review.

8.

A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR.

Surade S, Ty N, Hengrung N, Lechartier B, Cole ST, Abell C, Blundell TL.

Biochem J. 2014 Mar 1;458(2):387-94. doi: 10.1042/BJ20131127.

PMID:
24313835
9.

In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.

Lechartier B, Hartkoorn RC, Cole ST.

Antimicrob Agents Chemother. 2012 Nov;56(11):5790-3. doi: 10.1128/AAC.01476-12. Epub 2012 Aug 27.

10.

[Latent M. tuberculosis infection, update 2011].

Lechartier B, Mazza-Stalder J, Janssens JP, Nicod LP.

Rev Med Suisse. 2011 Nov 23;7(318):2289-94. Review. French.

PMID:
22400364

Supplemental Content

Loading ...
Support Center